Research ExplorerPublicationsPhase I clinical and magnetic resonance imaging study of the...

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).

Standard

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). / Laarhoven, van; Fiedler, Walter; Fiedler, Walter; Desar, Ingrid M E; Asten, van; Jack, J A; Marréaud, Sandrine; Lacombe, Denis; Govaerts, Anne-Sophie; Bogaerts, Jan; Lasch, Peter; Timmer-Bonte, Johanna N H; Lambiase, Antonio; Bordignon, Claudio; Punt, Cornelis J A; Heerschap, Arend; Herpen, van; Carla, M L.

In: CLIN CANCER RES, Vol. 16, No. 4, 4, 2010, p. 1315-1323.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Laarhoven, V, Fiedler, W, Fiedler, W, Desar, IME, Asten, V, Jack, JA, Marréaud, S, Lacombe, D, Govaerts, A-S, Bogaerts, J, Lasch, P, Timmer-Bonte, JNH, Lambiase, A, Bordignon, C, Punt, CJA, Heerschap, A, Herpen, V & Carla, ML 2010, 'Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).', CLIN CANCER RES, vol. 16, no. 4, 4, pp. 1315-1323. <http://www.ncbi.nlm.nih.gov/pubmed/20145168?dopt=Citation>

APA

Laarhoven, V., Fiedler, W., Fiedler, W., Desar, I. M. E., Asten, V., Jack, J. A., Marréaud, S., Lacombe, D., Govaerts, A-S., Bogaerts, J., Lasch, P., Timmer-Bonte, J. N. H., Lambiase, A., Bordignon, C., Punt, C. J. A., Heerschap, A., Herpen, V., & Carla, M. L. (2010). Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). CLIN CANCER RES, 16(4), 1315-1323. [4]. http://www.ncbi.nlm.nih.gov/pubmed/20145168?dopt=Citation

Vancouver

Laarhoven V, Fiedler W, Fiedler W, Desar IME, Asten V, Jack JA et al. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). CLIN CANCER RES. 2010;16(4):1315-1323. 4.

Bibtex

@article{b63e60be307a44dd97c38b981b7e8995,
title = "Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).",
abstract = "This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine the (a) dose-limiting toxicities, (b) maximum tolerated dose (MTD), (c) pharmacokinetics and pharmacodynamics, (d) vascular response by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and (e) preliminary clinical activity in solid tumors.",
author = "van Laarhoven and Walter Fiedler and Walter Fiedler and Desar, {Ingrid M E} and van Asten and Jack, {J A} and Sandrine Marr{\'e}aud and Denis Lacombe and Anne-Sophie Govaerts and Jan Bogaerts and Peter Lasch and Timmer-Bonte, {Johanna N H} and Antonio Lambiase and Claudio Bordignon and Punt, {Cornelis J A} and Arend Heerschap and van Herpen and Carla, {M L}",
year = "2010",
language = "Deutsch",
volume = "16",
pages = "1315--1323",
journal = "CLIN CANCER RES",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).

AU - Laarhoven, van

AU - Fiedler, Walter

AU - Fiedler, Walter

AU - Desar, Ingrid M E

AU - Asten, van

AU - Jack, J A

AU - Marréaud, Sandrine

AU - Lacombe, Denis

AU - Govaerts, Anne-Sophie

AU - Bogaerts, Jan

AU - Lasch, Peter

AU - Timmer-Bonte, Johanna N H

AU - Lambiase, Antonio

AU - Bordignon, Claudio

AU - Punt, Cornelis J A

AU - Heerschap, Arend

AU - Herpen, van

AU - Carla, M L

PY - 2010

Y1 - 2010

N2 - This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine the (a) dose-limiting toxicities, (b) maximum tolerated dose (MTD), (c) pharmacokinetics and pharmacodynamics, (d) vascular response by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and (e) preliminary clinical activity in solid tumors.

AB - This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine the (a) dose-limiting toxicities, (b) maximum tolerated dose (MTD), (c) pharmacokinetics and pharmacodynamics, (d) vascular response by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and (e) preliminary clinical activity in solid tumors.

M3 - SCORING: Zeitschriftenaufsatz

VL - 16

SP - 1315

EP - 1323

JO - CLIN CANCER RES

JF - CLIN CANCER RES

SN - 1078-0432

IS - 4

M1 - 4

ER -